Free Trial

Capstone Therapeutics (CAPS) Financials

Capstone Therapeutics logo
$1.74 -0.01 (-0.29%)
As of 12:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Capstone Therapeutics

Annual Income Statements for Capstone Therapeutics

This table shows Capstone Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.17 -2.77 -0.66 1.76 0.38 -5.74 -5.50 -22
Consolidated Net Income / (Loss)
-4.17 -2.77 -1.61 1.76 0.38 -3.82 -2.56 -21
Net Income / (Loss) Continuing Operations
-4.17 -2.77 -1.61 -1.61 -3.98 -4.11 -3.50 -21
Total Pre-Tax Income
-4.57 -2.96 -1.67 1.79 0.43 -3.59 -2.12 -14
Total Operating Income
-4.52 -2.94 -1.58 1.68 0.18 -1.26 -0.64 -11
Total Gross Profit
0.00 0.00 0.00 0.00 -2.00 9.61 9.57 11
Total Revenue
0.00 0.00 0.00 0.00 -2.00 48 44 47
Operating Revenue
- - - 0.00 -2.00 48 44 47
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 39 35 36
Operating Cost of Revenue
- - - - - 39 35 36
Total Operating Expenses
4.52 2.94 1.58 1.68 2.18 11 10 22
Selling, General & Admin Expense
1.45 1.76 0.54 -0.64 -0.55 11 10 14
Impairment Charge
- - - - - - - 6.20
Restructuring Charge
- - - - - - - 1.20
Other Special Charges / (Income)
- - - - - - - 0.01
Total Other Income / (Expense), net
-0.04 -0.02 -0.08 0.11 0.25 -2.33 -1.48 -3.06
Interest Expense
- - - - - -5.53 1.48 3.89
Other Income / (Expense), net
-0.04 -0.02 -0.08 0.11 0.25 0.14 0.00 0.83
Income Tax Expense
-0.40 -0.19 -0.06 0.04 0.05 0.23 0.44 7.18
Preferred Stock Dividends Declared
- - - - - - - 0.71
Basic Earnings per Share
$0.10 $0.07 $0.02 ($0.04) ($0.01) ($36.39) ($34.87) ($4.12)
Weighted Average Basic Shares Outstanding
40.89M 40.89M 40.89M 47.17K 54.39M 157.61K 157.61K 5.32M

Quarterly Income Statements for Capstone Therapeutics

This table shows Capstone Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.15 -1.33 -1.00 0.33 -2.43 -0.70 -2.01 -12 -1.92 -1.38
Consolidated Net Income / (Loss)
-0.73 -0.38 0.03 -2.25 -1.73 -0.70 -2.01 -19 -1.92 -1.38
Net Income / (Loss) Continuing Operations
-0.73 -0.38 0.03 -3.18 -1.73 -0.70 -2.01 -19 -1.92 -1.38
Total Pre-Tax Income
-1.10 -0.38 0.04 -0.68 -1.73 -0.70 -2.01 -9.61 -1.91 -1.38
Total Operating Income
-0.72 0.01 0.41 -0.35 -1.43 -0.26 -0.77 -8.53 -1.50 0.43
Total Gross Profit
1.75 2.76 2.99 2.07 1.33 3.13 3.25 3.08 2.97 6.00
Total Revenue
9.36 13 12 9.38 7.90 13 14 12 13 21
Operating Revenue
9.36 13 12 9.38 7.90 13 14 12 13 21
Total Cost of Revenue
7.61 10 9.33 8.25 6.57 9.72 10 9.39 9.67 15
Operating Cost of Revenue
7.61 10 9.33 8.25 6.57 9.72 10 9.39 9.67 15
Total Operating Expenses
2.46 2.75 2.58 2.42 2.75 3.39 4.02 12 4.47 5.57
Selling, General & Admin Expense
2.46 2.75 2.58 2.42 2.75 3.39 3.37 4.86 4.47 5.51
Other Special Charges / (Income)
- - - - - - - - - 0.06
Total Other Income / (Expense), net
0.00 -0.39 -0.37 -1.48 -0.30 -0.44 -1.25 -2.41 -0.42 -1.81
Interest Expense
- 0.39 0.37 - 0.30 0.44 1.25 - 0.89 1.96
Other Income / (Expense), net
- - - - 0.00 - - - 0.48 0.15
Income Tax Expense
0.02 0.00 0.01 0.42 0.00 0.00 0.00 7.18 0.00 0.00
Preferred Stock Dividends Declared
- 0.95 1.03 - 0.71 0.00 0.00 - 0.00 0.00
Basic Earnings per Share
($12.91) ($8.43) ($6.33) ($7.20) ($1.56) ($0.13) ($0.34) ($3.17) ($0.21) ($0.11)
Weighted Average Basic Shares Outstanding
157.61K 157.61K 157.61K 157.61K 1.56M 5.24M 5.84M 5.32M 9.33M 12.64M
Weighted Average Diluted Shares Outstanding
157.61K - - 157.61K - - - 0.00 12.63M 20.58M
Weighted Average Basic & Diluted Shares Outstanding
- - - 5.19M - - - 0.00 12.63M 20.58M

Annual Cash Flow Statements for Capstone Therapeutics

This table details how cash moves in and out of Capstone Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-4.09 -1.15 -0.31 0.58 0.07 0.03 -0.04 0.72
Net Cash From Operating Activities
-4.09 -2.15 -1.26 -1.56 0.07 1.65 3.82 -4.41
Net Cash From Continuing Operating Activities
-4.09 -2.15 -1.26 1.95 0.83 1.65 3.82 -4.41
Net Income / (Loss) Continuing Operations
-4.17 -2.77 -1.61 1.76 0.38 -3.82 -2.56 -21
Consolidated Net Income / (Loss)
-4.17 -2.77 -1.61 -1.76 -0.38 -3.82 -2.56 -21
Depreciation Expense
0.16 0.16 - - - 0.46 0.52 0.39
Non-Cash Adjustments To Reconcile Net Income
0.05 0.17 0.04 0.07 0.25 0.80 0.00 8.52
Changes in Operating Assets and Liabilities, net
-0.14 0.29 0.14 -0.08 0.04 4.21 5.87 7.91
Net Cash From Investing Activities
0.00 0.00 0.00 0.00 0.00 -0.21 -0.12 -6.91
Net Cash From Continuing Investing Activities
0.00 0.00 0.00 0.00 0.00 -0.21 -0.12 -6.91
Purchase of Property, Plant & Equipment
- - - - - -0.21 -0.12 -0.12
Acquisitions
- - - - - - - -6.79
Net Cash From Financing Activities
0.00 1.00 0.95 2.14 0.00 -1.41 -3.74 12
Net Cash From Continuing Financing Activities
0.00 1.00 0.95 2.14 0.00 -1.41 -3.74 12
Repayment of Debt
0.00 - 0.00 -1.00 0.00 -2.14 -1.01 0.72
Issuance of Debt
- 1.00 - 2.14 - 1.30 -2.32 6.53
Issuance of Common Equity
- - 0.00 1.01 0.00 -0.39 0.00 5.03
Other Financing Activities, net
- 0.00 0.00 -0.02 0.00 -0.18 -0.22 -0.16
Cash Interest Paid
- - - - - 1.65 1.50 0.87
Cash Income Taxes Paid
- - - - - 0.38 0.03 0.03

Quarterly Cash Flow Statements for Capstone Therapeutics

This table details how cash moves in and out of Capstone Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
-0.02 -0.03 0.01 -0.00 1.73 -0.97 -0.04 -0.00 -0.31 -0.19
Net Cash From Operating Activities
-1.24 0.11 2.22 2.73 -2.27 -1.72 - -0.42 -2.79 -0.39
Net Cash From Continuing Operating Activities
-1.24 0.11 2.22 2.73 -2.27 -1.72 - -0.42 -2.79 -0.39
Net Income / (Loss) Continuing Operations
-1.11 -0.38 0.03 -1.10 -1.73 -0.70 -2.01 -17 -1.92 -1.38
Consolidated Net Income / (Loss)
-1.11 -0.38 0.03 -1.10 -1.73 -0.70 -2.01 -17 -1.92 -1.38
Depreciation Expense
0.12 0.12 0.12 0.15 0.12 0.11 0.12 0.04 0.16 0.16
Non-Cash Adjustments To Reconcile Net Income
0.00 - - - -0.01 -0.01 - 7.87 0.16 1.64
Changes in Operating Assets and Liabilities, net
-0.25 0.37 2.06 3.69 -0.65 -1.12 1.02 8.71 -1.20 -0.82
Net Cash From Investing Activities
-0.10 -0.02 0.02 -0.02 -0.02 0.02 -2.44 -4.47 -0.03 -0.10
Net Cash From Continuing Investing Activities
-0.10 -0.02 0.02 -0.02 -0.02 0.02 -2.44 -4.47 -0.03 -0.10
Purchase of Property, Plant & Equipment
-0.10 -0.02 0.02 -0.02 -0.02 0.02 - -0.12 -0.03 -0.06
Net Cash From Financing Activities
1.32 -0.12 -2.23 -2.72 4.02 0.74 2.40 4.97 2.51 0.30
Net Cash From Continuing Financing Activities
1.32 -0.12 -2.23 -2.72 4.02 0.74 2.40 4.97 2.51 0.30
Repayment of Debt
-0.25 -0.26 -0.26 -0.26 0.57 -0.00 -0.39 1.70 2.38 -0.02
Issuance of Debt
1.61 0.18 -1.96 -2.15 0.00 0.98 2.83 1.24 0.20 0.43
Other Financing Activities, net
-0.04 -0.04 -0.02 -0.11 0.17 -0.24 -0.04 0.27 -0.07 -0.10
Effect of Exchange Rate Changes
- - - - 0.00 - - - -0.00 -0.00
Cash Interest Paid
0.38 0.39 0.37 0.35 0.30 0.44 0.59 -0.46 0.30 -0.30

Annual Balance Sheets for Capstone Therapeutics

This table presents Capstone Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2023 12/31/2024 12/31/2025
Total Assets
3.39 1.77 1.18 1.57 1.48 53 47 51
Total Current Assets
2.72 1.26 0.83 1.37 1.44 17 13 23
Cash & Equivalents
2.16 1.01 0.70 1.28 1.34 0.05 0.01 0.73
Accounts Receivable
- - - - - 2.58 2.76 4.86
Inventories, net
- - - - - 14 9.64 17
Prepaid Expenses
- - - - - 0.46 0.15 0.23
Other Current Assets
0.56 0.25 0.13 0.10 0.10 0.24 0.24 0.12
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 1.76 1.59 2.09
Total Noncurrent Assets
0.67 0.51 0.35 0.20 0.04 34 33 26
Goodwill
- - - - - 23 23 18
Intangible Assets
0.67 0.51 0.35 0.20 0.04 0.01 0.05 1.84
Other Noncurrent Operating Assets
- - - - - 2.97 2.32 5.99
Total Liabilities & Shareholders' Equity
3.39 1.77 1.18 1.57 1.48 53 47 51
Total Liabilities
0.28 1.26 1.30 2.45 2.72 24 21 39
Total Current Liabilities
0.28 0.26 0.30 0.20 0.25 16 13 23
Short-Term Debt
- - - - - 12 8.11 14
Accounts Payable
0.12 0.25 0.25 0.20 0.25 2.58 3.30 5.65
Accrued Expenses
0.16 0.01 0.06 0.00 0.00 0.32 0.39 0.87
Current Deferred & Payable Income Tax Liabilities
- - - - - - - 0.02
Other Current Liabilities
- - - - - 0.89 0.74 2.36
Total Noncurrent Liabilities
0.00 1.00 1.00 2.25 2.48 7.61 8.11 16
Long-Term Debt
- 1.00 0.00 2.25 2.48 5.11 6.32 9.04
Capital Lease Obligations
- - - - - 2.14 1.44 3.83
Other Noncurrent Operating Liabilities
0.00 - 1.00 - - 0.35 0.35 2.82
Total Equity & Noncontrolling Interests
3.10 0.51 -0.12 -0.88 -1.24 29 -3.06 12
Total Preferred & Common Equity
3.10 0.51 -0.12 -0.88 -1.24 2.44 -3.06 12
Preferred Stock
- - - - - 27 0.00 0.03
Total Common Equity
3.10 0.51 -0.12 -0.88 -1.24 2.44 -3.06 12
Common Stock
189 189 189 190 191 193 193 230
Retained Earnings
-186 -189 -190 -191 -192 -191 -196 -218
Accumulated Other Comprehensive Income / (Loss)
- - - - - - - -0.00

Quarterly Balance Sheets for Capstone Therapeutics

This table presents Capstone Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
52 52 58 54 55
Total Current Assets
17 17 19 26 27
Cash & Equivalents
1.74 0.77 0.73 0.42 0.23
Accounts Receivable
4.52 5.49 5.77 6.90 9.38
Inventories, net
9.78 9.59 12 18 16
Prepaid Expenses
0.42 0.44 0.20 0.44 0.27
Other Current Assets
0.24 0.24 0.24 0.17 0.60
Plant, Property, & Equipment, net
1.53 1.47 1.70 2.00 1.96
Total Noncurrent Assets
34 34 38 26 26
Goodwill
23 23 26 18 18
Intangible Assets
0.06 0.06 0.36 1.81 1.76
Other Noncurrent Operating Assets
3.45 3.36 4.10 5.55 5.62
Total Liabilities & Shareholders' Equity
52 52 58 54 55
Total Liabilities
25 26 31 43 42
Total Current Liabilities
15 17 20 27 27
Short-Term Debt
8.71 12 12 17 17
Accounts Payable
4.38 3.60 5.48 7.65 7.51
Accrued Expenses
0.75 0.92 1.33 0.92 1.20
Current Deferred & Payable Income Tax Liabilities
- - - 0.04 0.03
Other Current Liabilities
0.82 0.83 1.22 1.73 1.52
Total Noncurrent Liabilities
11 8.64 11 15 15
Long-Term Debt
7.54 5.83 7.23 8.79 8.60
Capital Lease Obligations
2.69 2.46 2.81 3.49 3.55
Other Noncurrent Operating Liabilities
0.35 0.35 1.27 2.86 3.00
Total Equity & Noncontrolling Interests
27 26 27 11 12
Total Preferred & Common Equity
27 26 27 11 12
Preferred Stock
0.00 0.03 1.97 0.03 0.03
Total Common Equity
27 26 25 11 12
Common Stock
226 225 226 231 234
Retained Earnings
-199 -199 -201 -220 -221
Accumulated Other Comprehensive Income / (Loss)
- - - 0.01 -0.05

Annual Metrics And Ratios for Capstone Therapeutics

This table displays calculated financial ratios and metrics derived from Capstone Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 40,885,411.00 54,385,411.00 54,385,411.00 54,385,411.00 54,385,411.00 5,190,251.00
DEI Adjusted Shares Outstanding
0.00 0.00 40,885,411.00 54,385,411.00 54,385,411.00 54,385,411.00 54,385,411.00 5,190,251.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -0.02 0.03 0.01 -0.11 -0.10 -4.23
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.57% 6.68%
EBITDA Growth
-6.97% 36.33% 47.04% 234.32% -70.49% 0.00% 81.44% -7,971.07%
EBIT Growth
-6.38% 35.12% 43.81% 207.57% -75.88% 0.00% 42.68% -1,492.01%
NOPAT Growth
-5.38% 35.04% 46.10% 248.47% -90.33% 0.00% 49.20% -1,621.94%
Net Income Growth
-1.29% 33.50% 41.93% 209.07% -78.35% 0.00% 32.89% -728.33%
EPS Growth
0.00% -30.00% -71.43% -300.00% 75.00% 0.00% 4.18% 0.00%
Operating Cash Flow Growth
-3.62% 47.41% 41.52% -23.99% 104.23% 0.00% 131.58% -215.47%
Free Cash Flow Firm Growth
-9.56% 48.73% 112.78% 254.62% -50.19% 0.00% 0.00% -174.26%
Invested Capital Growth
-2.09% -47.28% -265.66% 111.59% -215.79% 0.00% -12.55% -8.25%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% -200.00% 0.00% 0.00% 7.07%
EBITDA Q/Q Growth
-3.18% 2.06% 25.85% 228.11% -80.33% 0.00% 0.00% -323.69%
EBIT Q/Q Growth
-3.02% 1.92% 23.55% 214.96% -85.58% 0.00% 0.00% -262.23%
NOPAT Q/Q Growth
-2.05% -1.94% 25.49% 260.75% -94.59% 0.00% 0.00% -291.80%
Net Income Q/Q Growth
4.49% -14.36% 24.25% 213.67% -87.09% 0.00% 0.00% -261.12%
EPS Q/Q Growth
-9.09% 0.00% -33.33% 0.00% 66.67% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-0.54% 12.97% 13.53% 0.06% -41.59% 0.00% 0.00% -250.72%
Free Cash Flow Firm Q/Q Growth
-9.64% 27.59% 56.45% 135.69% -89.10% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
83.76% -31.35% 8.79% -24.60% 59.41% 0.00% 0.00% -19.68%
Profitability Metrics
- - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 20.00% 21.78% 23.02%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -1.36% -0.28% -20.83%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2.61% -1.45% -23.43%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -2.32% -1.45% -21.67%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -7.95% -5.83% -45.28%
Tax Burden Percent
91.24% 93.52% 96.64% 97.99% 87.96% 106.53% 120.84% 151.06%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 322.10% 332.45% 138.37%
Effective Tax Rate
0.00% 0.00% 0.00% 2.01% 12.04% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -1.81% -0.98% -18.91%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -16.97% -12.99% -82.88%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% -11.30% -8.22% -89.93%
Return on Equity (ROE)
-80.76% -153.56% -838.02% -350.65% -35.80% -13.11% -9.21% -108.84%
Cash Return on Invested Capital (CROIC)
-331.59% -225.01% 0.00% 769.72% 0.00% 0.00% 12.41% -10.30%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -2.11% -1.28% -20.60%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -7.25% -5.13% -43.06%
Return on Common Equity (ROCE)
-80.76% -153.56% -838.02% -350.65% -35.80% -1.10% 0.10% -26.13%
Return on Equity Simple (ROE_SIMPLE)
-134.29% -547.63% 1,318.85% -199.66% -30.55% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.17 -2.06 -1.11 1.65 0.16 -0.88 -0.45 -7.69
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -1.83% -1.02% -16.40%
Net Nonoperating Expense Percent (NNEP)
-23.75% -65.63% -141.10% -78.82% -20.95% 15.16% 12.01% 63.97%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -1.81% -3.48% -19.40%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 80.61% 80.34% 76.98%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 22.61% 23.23% 30.66%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 22.61% 23.23% 46.48%
Earnings before Interest and Taxes (EBIT)
-4.57 -2.96 -1.67 1.79 0.43 -1.11 -0.64 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.41 -2.81 -1.49 2.00 0.59 -0.65 -0.12 -9.77
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
3.04 10.50 0.00 0.00 0.00 1.03 0.00 0.07
Price to Tangible Book Value (P/TBV)
3.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.05 0.06 0.02
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 2.58 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 82,674.41% 38.82% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
7.75 10.72 0.00 10.28 0.00 1.00 1.13 0.70
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 1.01 1.09 0.58
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.49 3.59 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.55 4.89 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.59 13.27 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 32.01 29.45 12.56 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 10.49 1.33 5.80 0.00 8.51 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 1.98 0.00 -2.56 -1.99 0.67 0.60 2.18
Long-Term Debt to Equity
0.00 1.98 0.00 -2.56 -1.99 0.25 0.29 1.03
Financial Leverage
-0.82 -0.60 -1.85 -0.28 -0.99 0.67 0.63 1.09
Leverage Ratio
1.04 1.43 7.68 -2.75 -1.43 1.81 1.79 2.53
Compound Leverage Factor
1.04 1.43 7.68 -2.75 -1.43 5.83 5.97 3.50
Debt to Total Capital
0.00% 66.40% 0.00% 164.16% 201.06% 40.03% 37.41% 68.59%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 25.09% 19.12% 36.12%
Long-Term Debt to Total Capital
0.00% 66.40% 0.00% 164.16% 201.06% 14.94% 18.29% 32.48%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 54.95% 0.00% 0.08%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 69.80% 0.00%
Common Equity to Total Capital
100.00% 33.60% 100.00% -64.16% -101.06% 5.02% -7.21% 31.33%
Debt to EBITDA
0.00 -0.36 0.00 1.13 4.20 -29.82 -131.19 -2.78
Net Debt to EBITDA
0.00 0.00 0.00 0.49 1.93 -29.74 -131.10 -2.71
Long-Term Debt to EBITDA
0.00 -0.36 0.00 1.13 4.20 -11.13 -64.13 -1.32
Debt to NOPAT
0.00 -0.49 0.00 1.37 15.55 -22.11 -35.54 -3.54
Net Debt to NOPAT
0.00 0.01 0.00 0.59 7.12 -22.05 -35.52 -3.44
Long-Term Debt to NOPAT
0.00 -0.49 0.00 1.37 15.55 -8.25 -17.38 -1.67
Altman Z-Score
-60.50 -152.04 -227.39 -166.10 -180.96 -4.13 -4.85 -5.67
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 91.63% 101.12% 76.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
9.64 4.82 2.73 6.90 5.85 1.07 1.02 0.99
Quick Ratio
7.67 3.87 2.30 6.41 5.45 0.16 0.22 0.24
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.15 -1.61 0.21 0.73 0.36 0.00 5.64 -4.19
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 793.27% 3,184.17% -3,616.39%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 3.80 -1.08
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 2.58 -1.14
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 2.50 -1.17
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.91 0.88 0.95
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 18.62 16.45 12.30
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 2.82 3.02 2.70
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 27.37 26.24 25.49
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 15.05 12.01 8.06
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 19.60 22.19 29.69
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 129.54 120.88 135.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 24.26 30.39 45.29
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 124.88 112.68 119.39
Capital & Investment Metrics
- - - - - - - -
Invested Capital
0.94 0.50 -0.82 0.10 -0.11 49 42 39
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.99 0.97 1.15
Increase / (Decrease) in Invested Capital
-0.02 -0.44 -1.32 0.92 -0.21 0.00 -6.09 -3.50
Enterprise Value (EV)
7.28 5.30 2.16 0.98 2.11 49 48 27
Market Capitalization
9.44 5.32 2.86 0.00 0.98 2.52 2.52 0.91
Book Value per Share
$0.08 $0.01 $0.00 ($0.02) ($0.02) $0.04 ($0.06) $2.33
Tangible Book Value per Share
$0.06 $0.00 ($0.01) ($0.02) ($0.02) ($0.38) ($0.49) ($1.48)
Total Capital
3.10 1.51 -0.12 1.37 1.23 49 42 40
Total Debt
0.00 1.00 0.00 2.25 2.48 19 16 27
Total Long-Term Debt
0.00 1.00 0.00 2.25 2.48 7.26 7.76 13
Net Debt
-2.16 -0.01 -0.70 0.97 1.13 19 16 26
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.21 0.12 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.27 -0.01 -0.17 -0.10 -0.15 13 8.35 13
Debt-free Net Working Capital (DFNWC)
2.44 1.00 0.53 1.17 1.19 13 8.36 14
Net Working Capital (NWC)
2.44 1.00 0.53 1.17 1.19 1.11 0.25 -0.22
Net Nonoperating Expense (NNE)
1.00 0.71 0.50 -0.11 -0.22 2.94 2.12 14
Net Nonoperating Obligations (NNO)
-2.16 -0.01 -0.70 0.97 1.13 19 16 26
Total Depreciation and Amortization (D&A)
0.16 0.16 0.18 0.21 0.16 0.46 0.52 0.39
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 27.55% 19.01% 28.52%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 27.66% 19.03% 30.07%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2.31% 0.57% -0.47%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$100.00 $70.00 $20.00 $40.00 ($10.00) $0.00 ($34.87) ($4.12)
Adjusted Weighted Average Basic Shares Outstanding
0.00 40.89K 40.89K 54.39K 54.39K 0.00 157.61K 5.32M
Adjusted Diluted Earnings per Share
$100.00 $70.00 $20.00 $40.00 ($10.00) $0.00 ($34.87) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
0.00 40.89K 40.89K 54.39K 54.39K 0.00 157.61K 0.00
Adjusted Basic & Diluted Earnings per Share
$100.00 $70.00 $20.00 $40.00 ($10.00) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
40.89K 40.89K 40.89K 47.17K 54.00 0.00 5.19M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-3.17 -2.06 -1.11 1.65 0.16 -0.88 -0.45 -2.50
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -1.83% -1.02% -5.33%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -7.46% -4.83% -29.98%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -0.43 -2.61
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -0.30 -1.98
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -0.51 -2.65
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -0.38 -2.01
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.76% 0.00%

Quarterly Metrics And Ratios for Capstone Therapeutics

This table displays calculated financial ratios and metrics derived from Capstone Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
54,385,411.00 54,385,411.00 54,385,411.00 54,385,411.00 5,190,251.00 5,190,251.00 5,190,251.00 5,190,251.00 5,190,251.00 12,625,905.00
DEI Adjusted Shares Outstanding
54,385,411.00 54,385,411.00 54,385,411.00 54,385,411.00 5,190,251.00 5,190,251.00 5,190,251.00 5,190,251.00 5,190,251.00 12,625,905.00
DEI Earnings Per Adjusted Shares Outstanding
-0.06 -0.02 -0.02 0.01 -0.47 -0.13 -0.39 -2.38 -0.37 -0.11
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% -15.60% -0.26% 10.85% 32.99% 59.97% 67.13%
EBITDA Growth
0.00% 0.00% 0.00% 0.00% -119.77% -207.35% -221.04% -4,208.12% 34.45% 611.64%
EBIT Growth
0.00% 0.00% 0.00% 0.00% -99.16% -1,957.14% -285.96% -2,351.15% 28.50% 324.62%
NOPAT Growth
0.00% 0.00% 0.00% 0.00% -99.16% -1,957.14% -249.31% -2,351.15% -4.83% 266.15%
Net Income Growth
0.00% 0.00% 0.00% 0.00% -135.74% -83.73% -6,023.53% -734.03% -10.82% -97.14%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
0.00% 0.00% 0.00% 0.00% -82.69% -1,710.28% 0.00% -115.36% -22.92% 77.37%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 106.54% 109.89%
Invested Capital Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.25% -9.06% -9.27%
Revenue Q/Q Growth
0.00% 37.69% -4.41% -23.84% -15.80% 62.70% 6.24% -8.63% 1.28% 69.99%
EBITDA Q/Q Growth
0.00% 122.78% 294.85% -136.69% -565.99% 88.87% -345.21% -1,205.69% 89.87% 186.86%
EBIT Q/Q Growth
0.00% 101.95% 2,850.00% -184.26% -310.34% 81.79% -195.38% -1,010.68% 88.03% 157.20%
NOPAT Q/Q Growth
0.00% 101.95% 3,573.99% -167.66% -310.34% 81.79% -195.38% -1,010.68% 82.45% 128.86%
Net Income Q/Q Growth
0.00% 48.02% 108.92% -6,720.59% 23.23% 59.49% -187.71% -832.17% 89.80% 27.94%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 108.62% 1,976.64% 23.04% -182.99% 24.06% 0.00% 0.00% -564.05% 86.02%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -0.95% -7.46% 94.96% 219.47% 52.82%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 4.11% 2.82% 6.71% -19.68% 3.20% 2.58%
Profitability Metrics
- - - - - - - - - -
Gross Margin
18.65% 21.45% 24.30% 22.04% 16.77% 24.35% 23.83% 24.70% 23.50% 27.93%
EBITDA Margin
-6.38% 1.06% 4.36% -2.10% -16.61% -1.14% -4.76% -68.03% -6.81% 3.48%
Operating Margin
-7.66% 0.11% 3.35% -3.71% -18.08% -2.02% -5.62% -68.37% -11.85% 2.01%
EBIT Margin
-7.66% 0.11% 3.35% -3.71% -18.08% -2.02% -5.62% -68.37% -8.08% 2.72%
Profit (Net Income) Margin
-7.83% -2.96% 0.28% -24.00% -21.88% -5.45% -14.75% -150.48% -15.16% -6.42%
Tax Burden Percent
66.82% 100.26% 87.18% 329.58% 100.00% 100.00% 100.00% 195.32% 100.10% 100.22%
Interest Burden Percent
153.00% -2,714.29% 9.44% 196.26% 121.01% 269.23% 262.24% 112.68% 187.37% -235.79%
Effective Tax Rate
0.00% 0.00% 12.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -2.69% -24.35% -2.65% -7.12% -55.16% -10.15% 1.96%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -15.34% -32.82% -8.06% -20.98% -115.65% -13.91% -5.06%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% -9.16% -20.92% -5.87% -16.45% -125.49% -16.80% -6.27%
Return on Equity (ROE)
0.00% 0.00% 0.00% -11.85% -45.27% -8.52% -23.57% -180.66% -26.96% -4.31%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 13.30% 0.00% 0.00% 0.00% -10.30% -8.87% -7.03%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -3.26% -14.71% -1.66% -4.21% -65.02% -7.87% 3.07%
Return on Assets (ROA)
0.00% 0.00% 0.00% -21.11% -17.80% -4.46% -11.04% -143.10% -14.76% -7.26%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% 0.13% -45.27% -8.51% -21.86% -43.37% -26.93% -4.31%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.50 0.01 0.36 -0.24 -1.00 -0.18 -0.54 -5.97 -1.05 0.30
NOPAT Margin
-5.36% 0.08% 2.92% -2.60% -12.65% -1.42% -3.94% -47.86% -8.29% 1.41%
Net Nonoperating Expense Percent (NNEP)
0.00% 0.00% 0.00% 12.65% 8.47% 5.41% 13.86% 60.49% 3.76% 7.02%
Return On Investment Capital (ROIC_SIMPLE)
- - - -1.90% -2.18% -0.39% -1.09% -15.06% -2.58% 0.73%
Cost of Revenue to Revenue
81.35% 78.55% 75.70% 87.89% 83.23% 75.65% 76.17% 75.30% 76.50% 72.07%
SG&A Expenses to Revenue
26.31% 21.34% 20.95% 25.75% 34.85% 26.38% 24.68% 38.96% 35.35% 25.65%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
26.31% 21.34% 20.95% 25.75% 34.85% 26.38% 29.46% 98.39% 35.35% 25.92%
Earnings before Interest and Taxes (EBIT)
-0.72 0.01 0.41 -0.35 -1.43 -0.26 -0.77 -8.53 -1.02 0.58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-0.60 0.14 0.54 -0.20 -1.31 -0.15 -0.65 -8.49 -0.86 0.75
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.11 0.09 0.07 0.07 0.75 0.42
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.83 0.78 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.06 0.07 0.05 0.04 0.02 0.16 0.09
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 1.13 0.46 0.47 0.51 0.70 0.93 0.83
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 1.09 0.48 0.50 0.57 0.58 0.72 0.57
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 12.56 7.23 22.22 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.60 0.70 0.76 0.81 2.18 2.62 2.34
Long-Term Debt to Equity
0.00 0.00 0.00 0.29 0.38 0.32 0.37 1.03 1.09 0.98
Financial Leverage
0.00 0.00 0.00 0.60 0.64 0.73 0.78 1.09 1.21 1.24
Leverage Ratio
0.00 0.00 0.00 1.79 1.94 1.97 2.15 2.53 2.78 2.75
Compound Leverage Factor
0.00 0.00 0.00 3.52 2.34 5.32 5.65 2.85 5.20 -6.49
Debt to Total Capital
0.00% 0.00% 0.00% 37.41% 41.25% 43.11% 44.79% 68.59% 72.35% 70.02%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 19.12% 18.97% 25.17% 24.39% 36.12% 42.07% 40.69%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 18.29% 22.28% 17.95% 20.40% 32.48% 30.27% 29.33%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.07% 4.00% 0.08% 0.07% 0.07%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 69.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 0.00% 0.00% -7.21% 58.75% 56.82% 51.21% 31.33% 27.58% 29.91%
Debt to EBITDA
0.00 0.00 0.00 -131.19 -22.65 -17.81 -9.56 -2.78 -3.15 -2.94
Net Debt to EBITDA
0.00 0.00 0.00 -131.10 -20.57 -17.12 -9.24 -2.71 -3.11 -2.91
Long-Term Debt to EBITDA
0.00 0.00 0.00 -64.13 -12.23 -7.41 -4.35 -1.32 -1.32 -1.23
Debt to NOPAT
0.00 0.00 0.00 -35.54 -20.06 -17.53 -11.22 -3.54 -3.79 -4.00
Net Debt to NOPAT
0.00 0.00 0.00 -35.52 -18.21 -16.85 -10.85 -3.44 -3.74 -3.97
Long-Term Debt to NOPAT
0.00 0.00 0.00 -17.38 -10.83 -7.30 -5.11 -1.67 -1.59 -1.68
Altman Z-Score
0.00 0.00 0.00 -4.83 -4.48 -4.53 -4.10 -5.57 -4.74 -4.46
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 101.12% 0.00% 0.11% 7.24% 76.00% 0.08% 0.16%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.00 0.00 0.00 1.02 1.14 0.97 0.95 0.99 0.95 0.99
Quick Ratio
0.00 0.00 0.00 0.22 0.43 0.37 0.32 0.24 0.27 0.35
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 0.00 0.00 -45 -46 -49 -2.47 2.95 4.51
Operating Cash Flow to CapEx
-1,242.00% 509.52% 0.00% 14,389.47% -13,347.06% 0.00% 0.00% -350.00% -9,617.24% -609.38%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -150.56 -103.63 -39.32 0.00 3.31 2.30
Operating Cash Flow to Interest Expense
0.00 0.27 5.94 0.00 -7.56 -3.92 0.00 0.00 -3.13 -0.20
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.22 5.99 0.00 -7.62 -3.88 0.00 0.00 -3.16 -0.23
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.88 0.81 0.82 0.75 0.95 0.97 1.13
Accounts Receivable Turnover
0.00 0.00 0.00 16.45 9.40 7.74 7.59 12.30 9.04 8.11
Inventory Turnover
0.00 0.00 0.00 3.02 3.50 3.53 2.87 2.70 2.81 3.46
Fixed Asset Turnover
0.00 0.00 0.00 26.24 27.79 28.96 25.71 25.49 29.30 35.16
Accounts Payable Turnover
0.00 0.00 0.00 12.01 7.82 9.41 6.38 8.06 6.51 8.09
Days Sales Outstanding (DSO)
0.00 0.00 0.00 22.19 38.82 47.18 48.11 29.69 40.36 45.02
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 120.88 104.21 103.36 127.10 135.00 129.67 105.49
Days Payable Outstanding (DPO)
0.00 0.00 0.00 30.39 46.69 38.79 57.20 45.29 56.06 45.09
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 112.68 96.34 111.75 118.00 119.39 113.97 105.42
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 0.00 0.00 42 44 45 48 39 40 41
Invested Capital Turnover
0.00 0.00 0.00 1.04 1.92 1.87 1.81 1.15 1.22 1.39
Increase / (Decrease) in Invested Capital
0.00 0.00 0.00 0.00 44 45 48 -3.50 -4.00 -4.21
Enterprise Value (EV)
0.00 0.00 0.00 48 20 21 25 27 37 34
Market Capitalization
2.52 20 20 2.52 3.01 2.25 1.64 0.91 8.42 5.23
Book Value per Share
$0.00 $0.00 $0.00 ($0.06) $0.50 $5.01 $4.31 $2.33 $1.20 $0.98
Tangible Book Value per Share
$0.00 $0.00 $0.00 ($0.49) $0.07 $0.55 ($0.21) ($1.48) ($0.97) ($0.62)
Total Capital
0.00 0.00 0.00 42 46 46 49 40 41 41
Total Debt
0.00 0.00 0.00 16 19 20 22 27 29 29
Total Long-Term Debt
0.00 0.00 0.00 7.76 10 8.29 10 13 12 12
Net Debt
0.00 0.00 0.00 16 17 19 21 26 29 29
Capital Expenditures (CapEx)
0.10 0.02 -0.02 0.02 0.02 -0.02 0.00 0.12 0.03 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 0.00 0.00 8.35 9.02 10 10 13 15 16
Debt-free Net Working Capital (DFNWC)
0.00 0.00 0.00 8.36 11 11 11 14 16 17
Net Working Capital (NWC)
0.00 0.00 0.00 0.25 2.05 -0.44 -0.91 -0.22 -1.44 -0.24
Net Nonoperating Expense (NNE)
0.23 0.39 0.33 2.01 0.73 0.52 1.48 13 0.87 1.68
Net Nonoperating Obligations (NNO)
0.00 0.00 0.00 16 17 19 21 26 29 29
Total Depreciation and Amortization (D&A)
0.12 0.12 0.12 0.15 0.12 0.11 0.12 0.04 0.16 0.16
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 19.01% 21.22% 24.52% 23.66% 28.52% 29.47% 27.20%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 19.03% 25.33% 26.34% 25.32% 30.07% 30.28% 27.57%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.57% 4.83% -1.04% -2.07% -0.47% -2.80% -0.41%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($7.20) ($0.47) ($0.13) ($0.34) ($3.17) ($0.21) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 157.61K 5.19M 5.24M 5.84M 5.32M 9.33M 12.64M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($7.20) ($0.47) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 157.61K 5.19M 0.00 0.00 0.00 12.63M 20.58M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 5.19M 0.00 0.00 0.00 0.00 12.63M 20.58M
Normalized Net Operating Profit after Tax (NOPAT)
-0.50 0.01 0.36 -0.24 -1.00 -0.18 -0.08 -5.97 -1.05 0.34
Normalized NOPAT Margin
-5.36% 0.08% 2.92% -2.60% -12.65% -1.42% -0.59% -47.86% -8.29% 1.60%
Pre Tax Income Margin
-11.72% -2.95% 0.32% -7.28% -21.88% -5.45% -14.75% -77.04% -15.14% -6.41%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.04 1.10 0.00 -4.76 -0.59 -0.62 0.00 -1.14 0.30
NOPAT to Interest Expense
0.00 0.02 0.96 0.00 -3.33 -0.41 -0.43 0.00 -1.17 0.15
EBIT Less CapEx to Interest Expense
0.00 -0.02 1.16 0.00 -4.82 -0.56 -0.62 0.00 -1.18 0.27
NOPAT Less CapEx to Interest Expense
0.00 -0.03 1.02 0.00 -3.39 -0.38 -0.43 0.00 -1.21 0.12
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -7.76% 0.00% -50.27% -33.34% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Capstone Holding Corp. (NASDAQ: CAPS) showed stronger operating momentum in Q2 2026, but profitability, liquidity and leverage remain significant concerns. Revenue increased to $21.5 million from $12.6 million in Q1 2026 and $12.9 million in Q2 2025. Gross profit rose to $6.0 million, while the gross margin improved to approximately 28.0%, compared with 23.5% in Q1 2026 and 24.4% in Q2 2025.

Operating performance also improved sequentially. The company generated operating income of $432,000 in Q2 2026, compared with operating losses of $1.5 million in Q1 2026, $8.5 million in Q4 2025 and $768,000 in Q3 2025. However, net interest expense increased to $2.0 million, leaving the company with a net loss of $1.4 million, or $0.11 per basic share. Although this was an improvement from the $1.9 million loss in Q1, CAPS has reported net losses in each provided quarter since Q1 2025.

Cash flow trends improved but remain weak. Operating cash outflow narrowed to $390,000 in Q2 2026 from $2.8 million in Q1 and $1.7 million in Q2 2025. Even so, cash declined from $419,000 to $225,000 during the quarter after investing and financing activity. With $27.1 million of current liabilities and $16.9 million of short-term debt, the company has limited liquidity and continues to rely on financing to support operations.

  • Revenue growth accelerated: Q2 2026 revenue rose approximately 70% sequentially and 67% year over year, continuing the broader increase from the $7.9 million reported in Q1 2025 and $9.4 million in Q4 2024.
  • Gross margins improved: The Q2 2026 gross margin was about 28.0%, up from 23.5% in Q1 2026 and 24.4% in Q2 2025, indicating better absorption of revenue costs.
  • Operating results turned positive: CAPS generated $432,000 of operating income in Q2 2026 after reporting operating losses in the preceding quarters.
  • Operating cash burn narrowed: Cash used in operations fell to $390,000 in Q2 from $2.8 million in Q1 2026, a meaningful sequential improvement.
  • Working capital remains mixed: Accounts receivable increased to $9.4 million from $6.9 million in Q1, while inventory declined to $16.4 million from $18.1 million. The inventory reduction may help liquidity, but the receivables increase requires continued collection monitoring.
  • Asset growth has been acquisition-related: Goodwill remains a large $18.5 million asset, while total assets increased to $54.7 million from $52.2 million in Q1 2025. Investors should monitor whether acquired assets generate sufficient earnings and cash flow.
  • CAPS remains unprofitable: The company recorded a $1.4 million Q2 2026 net loss and has accumulated retained earnings of negative $221.3 million.
  • Interest expense is consuming operating gains: Q2 interest expense rose to $2.0 million from $892,000 in Q1 2026, more than offsetting the company’s operating profit.
  • Liquidity is tight: Cash and equivalents fell to only $225,000, while current liabilities totaled $27.1 million. The current ratio was approximately 0.99, and cash plus accounts receivable covered only about 35% of current liabilities.
  • Debt and financing dependence remain high: Short- and long-term debt totaled approximately $25.5 million, or about $29.1 million including capital lease obligations. Q2 financing provided $302,000 of cash, suggesting the company still depends on borrowing and other financing to offset operating cash needs.

Overall, the latest quarter contained encouraging signs in revenue, margins and operating cash flow. However, the combination of recurring net losses, rising interest expense, minimal cash reserves and substantial short-term obligations leaves CAPS financially vulnerable. Sustained profitability and internally generated cash flow would be needed to materially improve the company’s risk profile.

11/16/26 01:07 PM ETAI Generated. May Contain Errors.

Capstone Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Capstone Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Capstone Therapeutics' net income appears to be on a downward trend, with a most recent value of -$21.23 million in 2025, falling from -$4.17 million in 2014. The previous period was -$2.56 million in 2024. See where experts think Capstone Therapeutics is headed by visiting Capstone Therapeutics' forecast page.

Capstone Therapeutics' total operating income in 2025 was -$10.99 million, based on the following breakdown:
  • Total Gross Profit: $10.79 million
  • Total Operating Expenses: $21.79 million

Over the last 11 years, Capstone Therapeutics' total revenue changed from $0.00 in 2014 to $46.88 million in 2025, a change of 4,688,100,000.0%.

In the past 5 quarters, Capstone Therapeutics' cash and equivalents has ranged from $225 thousand in Q2 2026 to $1.74 million in Q1 2025, and is currently $225 thousand as of their latest financial filing in Q2 2026.

Capstone Therapeutics had total debt of $27.20 million at the end of 2025, a 71.3% increase from 2024, and none in 2014.

Over the last 11 years, Capstone Therapeutics' book value per share changed from 0.08 in 2014 to 2.33 in 2025, a change of 2,975.8%.



Financial statements for NASDAQ:CAPS last updated on 10/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners